Healthcare (Mar 2024)

Successful Desensitization to Sorafenib and Imatinib—A Report of Two Cases and a Literature Review

  • Natasa Kusic,
  • Vesna Tomic Spiric,
  • Snezana Arandjelovic,
  • Aleksandra Peric Popadic,
  • Ivana Bozic Antic,
  • Milan Dimitrijevic,
  • Rada Miskovic,
  • Ljiljana Stefanovic,
  • Aleksandra Plavsic

DOI
https://doi.org/10.3390/healthcare12060601
Journal volume & issue
Vol. 12, no. 6
p. 601

Abstract

Read online

Background: Drug desensitization allows for safe administration of a drug to a patient with a previous hypersensitivity reaction. Successful desensitization protocols have been described for different medications, including protocols for oncology patients. Few cases of desensitization to sorafenib and imatinib have been described in the literature so far. Objective: The objective of this paper is to describe the process of the sorafenib and imatinib drug hypersensitivity diagnosis and desensitization process in two patients. Methods: Two oncology patients who experienced non-immediate hypersensitivity reactions to sorafenib and imatinib underwent desensitization to these drugs. We designed a protocol for the first patient and used a modified protocol from the literature for the second patient. Results: By using a slow desensitization technique and gradual tapering of corticosteroids and antihistamines, both patients reached the target dose of the incriminated drug. Conclusions: Desensitization to sorafenib and imatinib can be an effective therapeutic option in patients with hypersensitivity to those medications, without alternative treatment options.

Keywords